Complicated Skin and Skin Structure Infection
Links shared publicly online about this topic
Phase 2 study of torezolid for complicated skin and skin structure infections - MPR
empr.com — “Trius Therapeutics, Inc. announced results from its Phase 2 clinical trial evaluating the safety and efficacy of oral torezolid (TR-701) for the treatment of severe complicated skin and skin structure infections caused by gram-positive bacteria, especially drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).” View full resource at empr.com
Most Recently Shared on June 8, 2009 at 10:26 pm By:
MPR News: Phase 2 study of torezolid for complicated skin and skin structure infections: Trius Therapeu.. http://tinyurl.com/kp5pc5
Vibativ approved for complicated skin and skin structure infections - MPR
empr.com — “The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.” View full resource at empr.com
Most Recently Shared on September 18, 2009 at 3:41 pm By:
MPR News: Vibativ approved for complicated skin and skin structure infections: The FDA has approved Vib.. http://bit.ly/Dekw8
Theravance and Astellas Announce FDA Approval of Vibativ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
drugs.com — “Vibativ (telavancin) is used to treat complicated skin and skin structure infections. Includes Vibativ side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on September 17, 2009 at 2:10 am By:
FDA Approves Vibativ (telavancin) for treatment of Complicated Skin and Skin Structure Infections - http://bit.ly/Jjp08
Theravance And Astellas Announce FDA Approval Of VIBATIVTM (telavancin) For The Treatment Of Complicated Skin And Skin Structure Infections
medicalnewstoday.com — “Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult p” View full resource at medicalnewstoday.com
Most Recently Shared on September 14, 2009 at 1:13 pm By:
MNT Dermatology News Dermatology and Health News
Theravance And Astellas Announce FDA Approval Of VIBATIVTM (telavancin) For The Treatment Of Complicated Skin An.. http://bit.ly/wwEWm
Infectious Disease News - Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function |3984257
mdlinx.com — “Infectious Disease Medical Article: Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function” View full resource at mdlinx.com
Most Recently Shared on March 26, 2012 at 6:22 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infect... http://t.co/Qly6v4Qa #ID
Diabetes and Skin Complications
diabetes.org — “As many as 33 percent of people with diabetes will have a skin disorder caused or affected by diabetes at some time in their lives.” View full resource at diabetes.org
Most Recently Shared on January 18, 2010 at 12:11 am By:
Channing Barnett Doctor, Dermatologist, and Physician
Diabetes can affect every part of the body, including the skin. http://bit.ly/akv7QO
Skin on #MDlinx
mdlinx.com — “Skin on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on October 4, 2010 at 7:01 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole... http://bit.ly/cnI6Ao #medicine
Skin on #MDlinx
mdlinx.com — “Skin on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on October 4, 2010 at 5:27 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole: Ther... http://bit.ly/aHjTrx #ID
Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
medicalnewstoday.com — “Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces th” View full resource at medicalnewstoday.com
Most Recently Shared on November 7, 2009 at 1:19 pm By:
MNT Dermatology News Dermatology and Health News
Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infec.. http://bit.ly/2woxZM
Phase 3 study of torezolid for acute bacterial skin and skin structure infections - ONA
oncologynurseadvisor.com — “Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).” View full resource at oncologynurseadvisor.com
Most Recently Shared on August 30, 2010 at 8:30 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 study of torezolid for acute bacterial skin and skin structure infections http://goo.gl/fb/pYKK8
Phase 3 study of torezolid for acute bacterial skin and skin structure infections - MPR
empr.com — “Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).” View full resource at empr.com
Most Recently Shared on August 30, 2010 at 9:59 pm By:
MPR News: Phase 3 study of torezolid for acute bacterial skin and skin structure infections: Trius Therapeutics an... http://bit.ly/d9XLAi
Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections
news-medical.net — “Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).” View full resource at news-medical.net
Most Recently Shared on April 20, 2011 at 10:12 am By:
Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections: Durata Therape... http://bit.ly/eVjlet
Phase 2b study of delafloxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) - MPR
empr.com — “Rib-X Pharmaceuticals announced the initiation of a Phase 2b trial to evaluate delafloxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by methicillin-resistant Staphylococcus aureus (MRSA).” View full resource at empr.com
Most Recently Shared on February 9, 2011 at 10:14 pm By:
MPR News: Phase 2b study of delafloxacin for the treatment of acute bacterial skin and skin structure infections... http://bit.ly/dWDKr6
Phase 2 study of Taksta for the treatment of acute bacterial skin and skin structure infections (ABSSSI) - MPR
empr.com — “Cempra Pharmaceuticals announced positive results from its Phase 2 trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of Taksta (sodium fusidate) for patients suffering from acute bacterial skin and skin structure infections (ABSSSI).” View full resource at empr.com
Most Recently Shared on May 5, 2010 at 5:05 pm By:
MPR News: Phase 2 study of Taksta for the treatment of acute bacterial skin and skin structure infections (ABSSSI)... http://bit.ly/b5mkQX
Infectious Disease Article | Skin Diseases, Infectious
mdlinx.com — “Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections” View full resource at mdlinx.com
Most Recently Shared on January 31, 2011 at 11:35 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharma... http://bit.ly/hm5WGT #ID
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
Advertisement
